This trial was closed when Clark was turned away from NIH, but I have all the information about it written down in my notebook. Actually, “Bristol-Myers Squibb” is written in the doctor’s handwriting. I made a bunch of calls about it, but everything was full.
“The last drug approved was interleukin-2 in 1998, but it is so toxic it is rarely used. Neither it nor the other approved drug, dacarbazine, has clearly demonstrated improved survival.”
We wanted to buy him some time by shrinking his tumors so that he’d be able to receive a treatment at NIH that had a high percentage of curing him for good. But some people receiving the Yervoy aren’t expecting to live long lives; they just want a few more months than an advanced melanoma diagnosis would allow them.
“That price could spur continued debate about the cost of cancer drugs that prolong survival by only a few months on average.”
We never thought like that – in terms of squeezing out a little more life. The thought never entered my brain. We were either going to beat it, or we weren’t.